NYXFEXI
Live / Registered — Registered (as of 26 Mar 2024)
What this means for you
Registered since 26 Mar 2024. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97788278
- Registration number
- 7336173
- Mark type
- Stylized text
- Filed
- 09 Feb 2023
- Published for opposition
- 09 Jan 2024
- Registered
- 26 Mar 2024
- Attorney of record
- Elizabeth K. Rucki
Goods and services
- Class 005 — Pharmaceuticals: Vaccines; Anti-infectives; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders
Owner
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 26 Mar 2024 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 26 Mar 2024 — REGISTERED-PRINCIPAL REGISTER
- 09 Jan 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 09 Jan 2024 — PUBLISHED FOR OPPOSITION
- 20 Dec 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 06 Dec 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 05 Dec 2023 — EXAMINER'S AMENDMENT ENTERED
- 05 Dec 2023 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 05 Dec 2023 — EXAMINERS AMENDMENT E-MAILED
- 05 Dec 2023 — EXAMINERS AMENDMENT -WRITTEN
- 04 Dec 2023 — PREVIOUS ALLOWANCE COUNT WITHDRAWN
- 28 Nov 2023 — WITHDRAWN FROM PUB - OG REVIEW QUERY
- 16 Nov 2023 — ELECTRONIC RECORD REVIEW COMPLETE
- 10 Nov 2023 — ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
- 03 Nov 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER